Perrigo receives final approval from FDA for congestion relief tablets

Published on July 8, 2014 at 9:30 AM · No Comments

Perrigo Company (NYSE: PRGO; TASE) today announced that it was the first to receive final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ibuprofen and phenylephrine hydrochloride tablets, 200 mg/10 mg (over-the-counter), the store brand equivalent to Advil® Congestion Relief Tablets, 200 mg/10 mg. Perrigo expects to begin shipments of the product prior to the upcoming cough/cold/flu season.

Advil® Congestion Relief Tablets, 200 mg/10 mg, (ibuprofen & phenylephrine hydrochloride tablets, 200 mg/10 mg) is indicated for the relief of sinus pressure, nasal swelling and congestion, and headache. Estimated annual sales of the product are approximately $18 million.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This approval further strengthens our leading store brand position and highlights our commitment to bringing new affordable products to the market."

Source:

Perrigo Company

Posted in: Healthcare News | Pharmaceutical News

Tags: , , , , , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Scientists call for public to help monitor spread of flu across the UK